- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A shingles awareness advert in a lifestyle magazine, plus links/QR code to a company site and a patient organisation site, was ruled…
Anonymous burns-unit complainant alleged a ProStrakan medical liaison specialist promoted off-label Abstral and compared it with Actiq without data. Panel found complaint…
A caller sought advice on when to inject Clexane before a long flight. Sanofi declined to advise on a personal medical matter…
Anonymous complaint alleged unsolicited promotional emails to NHS staff about setting up ‘oral chemotherapy’ clinics without consent or prescribing info. Panel found…
Allergan alleged Merz’s FACE conference stand/leavepiece implied Bocouture and Botox were interchangeable/equivalent (1:1 conversion). Panel and Appeal Board held “comparable efficacy” did…
Three HCPs complained about an NVAF stroke-prevention online survey invite offering £70 plus extra £5 for “Switched to Pradaxa/Xarelto” forms. Survey wasn’t…
A patient alleged Pfizer failed to warn about seizures/convulsions with Champix. PMCPA found UK patient materials reflected the SPC/PIL at the time…
Ferring’s global office mistakenly mailed two Milan congress symposium flyers to 436 UK delegates. PMCPA ruled both flyers were promotional and uncertified…
A chief pharmacist complained about a Cipralex (escitalopram) promotional email sent via a database agency to local prescribers despite non-formulary status. The…
A British Journal of Clinical Pharmacy supplement branded as an “Educational update” about Octasa was ruled disguised promotion. Multiple misleading/unsubstantiated cost and…
Anonymous complaint about BJMA meeting sponsorship (Bolton, July 2013). Panel saw event as mainly social with limited science. Chiesi appealed: Clause 19.1…
Norgine alleged Galen’s prescribing policy on switching Movicol to Laxido Orange indirectly facilitated a prohibited switch programme. Panel and Appeal Board ruled…
AstraZeneca’s EMIS Web search guide for identifying patients for Forxiga was ruled misleading and inconsistent with the SPC, with undue weight-loss emphasis…
Actavis’ Levosert leavepiece implied broader suitability than Mirena and claimed a “25% saving” on acquisition cost. PMCPA ruled the claims misleading/unsubstantiated and…
Anonymous employee alleged Merck Serono neurology KAMs were pushed to achieve 6 calls/contacts per day. Panel found targets risked inconvenience and Code…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.